Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure

Lisa McFadden, Greg C. Hadlock, Scott C. Allen, Paula L. Vieira-Brock, Kristen A. Stout, Jonathan D. Ellis, Amanda J. Hoonakker, David M. Andrenyak, Shannon M. Nielsen, Diana G. Wilkins, Glen R. Hanson, Annette E. Fleckenstein

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Preclinical studies have demonstrated that repeated methamphetamine (METH) injections (referred to herein as a "binge" treatment) cause persistent dopaminergic deficits. A few studies have also examined the persistent neurochemical impact of METH self-administration in rats, but with variable results. These latter studies are important because: 1) they have relevance to the study of METH abuse; and 2) the effects of noncontingent METH treatment do not necessarily predict effects of contingent exposure. Accordingly, the present study investigated the impact of METH self-administration on dopaminergic neuronal function. Results revealed that self-administration of METH, given according to a regimen that produces brain METH levels comparable with those reported postmortem in human METH abusers (0.06 mg/infusion; 8-h sessions for 7 days), decreased striatal dopamine transporter (DAT) uptake and/or immunoreactivity as assessed 8 or 30 days after the last self-administration session. Increasing the METH dose per infusion did not exacerbate these deficits. These deficits were similar in magnitude to decreases in DAT densities reported in imaging studies of abstinent METH abusers. It is noteworthy that METH self-administration mitigated the persistent deficits in dopaminergic neuronal function, as well as the increases in glial fibrillary acidic protein immunoreactivity, caused by a subsequent binge METH exposure. This protection was independent of alterations in METH pharmacokinetics, but may have been attributable (at least in part) to a pretreatment-induced attenuation of binge-induced hyperthermia. Taken together, these results may provide insight into the neurochemical deficits reported in human METH abusers.

Original languageEnglish (US)
Pages (from-to)295-303
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume340
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Corpus Striatum
Self Administration
Methamphetamine
Dopamine Plasma Membrane Transport Proteins
Induced Hyperthermia
Glial Fibrillary Acidic Protein

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. / McFadden, Lisa; Hadlock, Greg C.; Allen, Scott C.; Vieira-Brock, Paula L.; Stout, Kristen A.; Ellis, Jonathan D.; Hoonakker, Amanda J.; Andrenyak, David M.; Nielsen, Shannon M.; Wilkins, Diana G.; Hanson, Glen R.; Fleckenstein, Annette E.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 340, No. 2, 01.02.2012, p. 295-303.

Research output: Contribution to journalArticle

McFadden, L, Hadlock, GC, Allen, SC, Vieira-Brock, PL, Stout, KA, Ellis, JD, Hoonakker, AJ, Andrenyak, DM, Nielsen, SM, Wilkins, DG, Hanson, GR & Fleckenstein, AE 2012, 'Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure', Journal of Pharmacology and Experimental Therapeutics, vol. 340, no. 2, pp. 295-303. https://doi.org/10.1124/jpet.111.188433
McFadden, Lisa ; Hadlock, Greg C. ; Allen, Scott C. ; Vieira-Brock, Paula L. ; Stout, Kristen A. ; Ellis, Jonathan D. ; Hoonakker, Amanda J. ; Andrenyak, David M. ; Nielsen, Shannon M. ; Wilkins, Diana G. ; Hanson, Glen R. ; Fleckenstein, Annette E. / Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. In: Journal of Pharmacology and Experimental Therapeutics. 2012 ; Vol. 340, No. 2. pp. 295-303.
@article{8d83f102e8a2459dbd228c8afe60b0dc,
title = "Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure",
abstract = "Preclinical studies have demonstrated that repeated methamphetamine (METH) injections (referred to herein as a {"}binge{"} treatment) cause persistent dopaminergic deficits. A few studies have also examined the persistent neurochemical impact of METH self-administration in rats, but with variable results. These latter studies are important because: 1) they have relevance to the study of METH abuse; and 2) the effects of noncontingent METH treatment do not necessarily predict effects of contingent exposure. Accordingly, the present study investigated the impact of METH self-administration on dopaminergic neuronal function. Results revealed that self-administration of METH, given according to a regimen that produces brain METH levels comparable with those reported postmortem in human METH abusers (0.06 mg/infusion; 8-h sessions for 7 days), decreased striatal dopamine transporter (DAT) uptake and/or immunoreactivity as assessed 8 or 30 days after the last self-administration session. Increasing the METH dose per infusion did not exacerbate these deficits. These deficits were similar in magnitude to decreases in DAT densities reported in imaging studies of abstinent METH abusers. It is noteworthy that METH self-administration mitigated the persistent deficits in dopaminergic neuronal function, as well as the increases in glial fibrillary acidic protein immunoreactivity, caused by a subsequent binge METH exposure. This protection was independent of alterations in METH pharmacokinetics, but may have been attributable (at least in part) to a pretreatment-induced attenuation of binge-induced hyperthermia. Taken together, these results may provide insight into the neurochemical deficits reported in human METH abusers.",
author = "Lisa McFadden and Hadlock, {Greg C.} and Allen, {Scott C.} and Vieira-Brock, {Paula L.} and Stout, {Kristen A.} and Ellis, {Jonathan D.} and Hoonakker, {Amanda J.} and Andrenyak, {David M.} and Nielsen, {Shannon M.} and Wilkins, {Diana G.} and Hanson, {Glen R.} and Fleckenstein, {Annette E.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1124/jpet.111.188433",
language = "English (US)",
volume = "340",
pages = "295--303",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure

AU - McFadden, Lisa

AU - Hadlock, Greg C.

AU - Allen, Scott C.

AU - Vieira-Brock, Paula L.

AU - Stout, Kristen A.

AU - Ellis, Jonathan D.

AU - Hoonakker, Amanda J.

AU - Andrenyak, David M.

AU - Nielsen, Shannon M.

AU - Wilkins, Diana G.

AU - Hanson, Glen R.

AU - Fleckenstein, Annette E.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Preclinical studies have demonstrated that repeated methamphetamine (METH) injections (referred to herein as a "binge" treatment) cause persistent dopaminergic deficits. A few studies have also examined the persistent neurochemical impact of METH self-administration in rats, but with variable results. These latter studies are important because: 1) they have relevance to the study of METH abuse; and 2) the effects of noncontingent METH treatment do not necessarily predict effects of contingent exposure. Accordingly, the present study investigated the impact of METH self-administration on dopaminergic neuronal function. Results revealed that self-administration of METH, given according to a regimen that produces brain METH levels comparable with those reported postmortem in human METH abusers (0.06 mg/infusion; 8-h sessions for 7 days), decreased striatal dopamine transporter (DAT) uptake and/or immunoreactivity as assessed 8 or 30 days after the last self-administration session. Increasing the METH dose per infusion did not exacerbate these deficits. These deficits were similar in magnitude to decreases in DAT densities reported in imaging studies of abstinent METH abusers. It is noteworthy that METH self-administration mitigated the persistent deficits in dopaminergic neuronal function, as well as the increases in glial fibrillary acidic protein immunoreactivity, caused by a subsequent binge METH exposure. This protection was independent of alterations in METH pharmacokinetics, but may have been attributable (at least in part) to a pretreatment-induced attenuation of binge-induced hyperthermia. Taken together, these results may provide insight into the neurochemical deficits reported in human METH abusers.

AB - Preclinical studies have demonstrated that repeated methamphetamine (METH) injections (referred to herein as a "binge" treatment) cause persistent dopaminergic deficits. A few studies have also examined the persistent neurochemical impact of METH self-administration in rats, but with variable results. These latter studies are important because: 1) they have relevance to the study of METH abuse; and 2) the effects of noncontingent METH treatment do not necessarily predict effects of contingent exposure. Accordingly, the present study investigated the impact of METH self-administration on dopaminergic neuronal function. Results revealed that self-administration of METH, given according to a regimen that produces brain METH levels comparable with those reported postmortem in human METH abusers (0.06 mg/infusion; 8-h sessions for 7 days), decreased striatal dopamine transporter (DAT) uptake and/or immunoreactivity as assessed 8 or 30 days after the last self-administration session. Increasing the METH dose per infusion did not exacerbate these deficits. These deficits were similar in magnitude to decreases in DAT densities reported in imaging studies of abstinent METH abusers. It is noteworthy that METH self-administration mitigated the persistent deficits in dopaminergic neuronal function, as well as the increases in glial fibrillary acidic protein immunoreactivity, caused by a subsequent binge METH exposure. This protection was independent of alterations in METH pharmacokinetics, but may have been attributable (at least in part) to a pretreatment-induced attenuation of binge-induced hyperthermia. Taken together, these results may provide insight into the neurochemical deficits reported in human METH abusers.

UR - http://www.scopus.com/inward/record.url?scp=84855993427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855993427&partnerID=8YFLogxK

U2 - 10.1124/jpet.111.188433

DO - 10.1124/jpet.111.188433

M3 - Article

VL - 340

SP - 295

EP - 303

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -